Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Experts consider continuous ambulatory oesophageal pH monitoring (CAOpHM) proven for reflux

This article was originally published in Clinica

Executive Summary

A panel of experts considers continuous ambulatory oesophageal pH monitoring (CAOpHM) both safe and effective for adults with clear symptoms of oesophageal damage. Dr Michael Glade, who works in the department of Technology Assessment at the American Medical Association sent a Diagnostic and Therapeutic Technology Assessment (DATTA) questionnaire to 118 physicians with recognised expertise in reflux, oesophageal disease, or the use of CAOpHM in the diagnosis of non-cardiac chest pain. The results are published in JAMA (August 23/30th).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT093391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel